We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Name | Symbol | Market | Type |
|---|---|---|---|
| Roche Holdings Ltd AG (QX) | USOTC:RHHBY | OTCMarkets | Depository Receipt |
| Price Change | % Change | Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.23 | 0.77% | 30.25 | 30.15 | 30.26 | 30.28 | 30.07 | 30.10 | 2,908,982 | 22:20:00 |
From Apr 2019 to Apr 2024
By Joshua Kirby
Roche Holding AG said Friday that it received an approval recommendation from a European Medicines Agency committee for Evrysdi, its spinal muscular atrophy treatment.
The Swiss pharmaceutical company said the EMA's committee for Medicinal Products for Human Use recommended the approval of Evrysdi in patients aged two months and older diagnosed with SMA of various types.
The recommendation was made under the accelerated assessment pathway for medicines considered to be of major public interest for public health, Roche said. A final decision from the EMA on the use of the treatment in the European Union is expected within the next two months, it added.
Write to Joshua Kirby at joshua.kirby@dowjones.com; @joshualeokirby
(END) Dow Jones Newswires
February 26, 2021 06:58 ET (11:58 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
1 Year Roche (QX) Chart |
1 Month Roche (QX) Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
